Related by context. All words. (Click for frequent words.) 72 IRLS 71 HDRS 70 MADRS score 69 PANSS 67 Crohn Disease Activity 67 CDAI 67 IBDQ 67 NIH CPSI 67 Score DAS# 67 CDAI score 67 Montgomery Asberg Depression 67 achieving PASI 67 DAS# CRP 67 lopinavir r arm 66 YMRS 66 REYATAZ r arm 66 ADHD RS 66 Index CDAI 66 lumbar spine BMD 66 UPDRS 65 CCyR 65 PASI scores 65 DAS# [002] 65 4mg/kg 65 UPDRS motor 65 ADAS cog 65 Index CDAI score 65 Montgomery Åsberg Depression 65 HAMD 65 HbA 1c levels 65 Hb A1C 64 ACR# response 64 EDSS scores 64 PANSS total 64 Rating Scale MADRS 64 serum urate 64 -#.# log# 64 elevated ALT 64 % Confidence Interval 64 Scale EDSS 64 Ishak fibrosis score 64 EDSS score 64 achieved ACR# 64 nasal symptom 64 Global Impression CGI 64 Y BOCS 64 tipranavir r 64 DLQI 64 ACR Pedi 64 ALT elevation 63 Psoriasis Area 63 SELENA SLEDAI score 63 ug kg 63 MMSE score 63 DAS# remission 63 sUA 63 PREZISTA r arm 63 APACHE II 63 mcg albinterferon alfa 2b 63 evaluable subjects 63 Brief Psychiatric 63 low dose Iluvien 63 receiving VICTRELIS 63 hours postdose 63 mg TID 63 mg ustekinumab 63 chlorambucil 63 oxycodone CR 62 8mg/kg 62 adjunctive placebo 62 liver histology 62 baseline HbA1c 62 point Likert scale 62 achieved PASI 62 highly emetogenic 62 certolizumab 62 CR nPR 62 mEq L 62 NIHSS 62 CR CRu 62 moderately emetogenic 62 Expanded Disability Status 62 clinically meaningful improvement 62 baseline PASI 62 CNS LS 62 ADCS CGIC 62 angiographic restenosis 62 HAQ DI 62 Scale EDSS score 62 mg BID dose 62 SGRQ 62 divalproex sodium 62 UPDRS scores 62 Severity Index PASI 61 hemoglobin A1c HbA1c 61 glycated hemoglobin levels 61 ARB telmisartan 61 oral diclofenac 61 postdose 61 mcg QD 61 tapentadol ER 61 mean baseline HbA1c 61 corticosteroid dose 61 Negative Syndrome 61 HAM D# 61 MADRS 61 p = .# [001] 61 plasma HCV RNA 61 HAM D# scores 61 nicardipine 61 splenectomized patients 61 #.#/#.# mmHg [001] 61 oral allopurinol 61 log# copies mL 61 NIHSS score 61 -#.# mg dL [002] 61 undetectable viral 61 PSQI 61 MoxDuo TM IR 61 undetectable HBV DNA 61 rizatriptan 61 ADCS ADL 61 ADAS Cog 61 preintervention 61 confirmed CCyR 61 IPSS 61 Alzheimer Disease Assessment 61 Global Impression 61 neutrophil counts 61 BPH Symptom Score 61 mg XP# 61 Operative mortality 61 insulin detemir 61 symptom severity 61 MMSE scores 61 hemoglobin A1c levels 61 nonfatal MI 61 #mg dose [002] 60 hypoglycemic events 60 endoscopic remission 60 mcg mL 60 Flu Cy 60 atorvastatin #mg 60 aspartate aminotransferase 60 MCyR 60 BPRS 60 mcg BID 60 HBeAg seroconversion 60 NNT = 60 Knodell necroinflammatory score 60 rhinoconjunctivitis 60 Disease Activity 60 Unified Parkinson Disease 60 TMC# r 60 binary restenosis 60 biopsy Gleason 60 ALT elevations 60 HbA 1c 60 + PH# 60 HbA1C levels 60 Scale cognitive subscale 60 HOMA IR 60 severe exacerbations 60 microbiological eradication 60 HBV DNA levels 60 subscore 60 Platelet counts 60 plus methotrexate 60 LS BMD 60 fluticasone salmeterol 60 ertapenem 60 cEVR 60 p = #.# [003] 60 TEAEs 60 mRS 60 placebo dexamethasone 60 mg QD 60 nondiabetic patients 60 #.#mg/dL 60 FOLFOX4 60 baseline A1C 60 μg dose 60 nodular partial response 60 Visual Analogue Scale VAS 60 mmol L. 60 abdominal pain abdominal discomfort 60 LEXIVA r 60 solifenacin 59 IU ml 59 serologically active patients 59 mg BID 59 secondary efficacy endpoint 59 apnea hypopnea index 59 Rating Scale BPRS 59 adefovir treated 59 mean baseline A1C 59 neutropaenia 59 albumin excretion rate 59 % CI #.#-#.# [007] 59 IOP lowering 59 mmol l 59 subscores 59 mTSS 59 HbA1c levels 59 annualized relapse 59 Pred Forte 59 elevated serum creatinine 59 comparator arm 59 complete cytogenetic response 59 CI -#.# 59 log# reduction 59 lopinavir r 59 systolic BP 59 fasting plasma glucose FPG 59 CIMZIA ™ 59 lispro 59 pT3 59 SSRI SNRI 59 apolipoprotein B 59 detectable HCV RNA 59 piperacillin tazobactam 59 glycated hemoglobin HbA1c 59 Engerix B 59 receiving golimumab 59 creatinine ratio 59 postintervention 59 p = NS 59 β blocker 59 mL/min/#.# m 2 59 receiving Vectibix monotherapy 59 mmHg diastolic 59 treat NNT 59 microg 59 salmeterol fluticasone 59 -#.# ± [002] 59 serum phosphate 59 Infusion Reactions Severe 59 CIMZIA TM 59 cytogenetic response 59 moderate renal impairment 59 quetiapine XR 59 metformin monotherapy 59 urate lowering therapy 59 tolterodine ER 59 QTcF 59 Scale PANSS 59 WOMAC pain 59 aminotransferase elevations greater 59 urinary N telopeptide 59 definite stent thrombosis 59 HBeAg negative patients 59 sd = 58 HADS 58 μg doses 58 abacavir lamivudine 58 Median PFS 58 receiving ISENTRESS 58 arterial thromboembolic events 58 biochemical relapse 58 AUA BPH Symptom Score 58 IELT 58 PERMP 58 alanine aminotransferase 58 #mmHg [001] 58 sustained virological response 58 plus dexamethasone 58 μmol L 58 REMICADE monotherapy 58 mg kg dose 58 TNSS 58 Cmax 58 Score DAS 58 lymphocytosis 58 WOMAC 58 Negative Symptoms 58 hematologic toxicity 58 elevated LDH 58 tipranavir ritonavir 58 ACR# ACR# 58 CANCIDAS 58 QIDS SR 58 Apidra ® 58 % CI #.#-#.# [003] 58 generalized edema 58 morphometric vertebral fractures 58 postvaccination 58 pCR 58 hip BMD 58 pegylated interferon alpha 58 X ULN 58 Lumbar spine 58 anemia hemoglobin 58 QRS duration 58 -#.# log# copies mL 58 mg qd 58 salivary flow 58 adjunctive ABILIFY 58 Health Assessment Questionnaire 58 hypophosphatemia 58 severe neutropenia 58 glycosylated hemoglobin HbA1c 58 remission CR 58 FluCAM arm 58 CRp 58 mg Proellex 58 preoperative PSA 58 HRQoL 58 haematologic 58 mm Hg systolic 58 PREZISTA ritonavir 58 asthma exacerbation 58 p = .# [002] 58 pulmonary capillary wedge 58 intramuscular dose 58 tolvaptan 58 quetiapine 58 μg mL 58 ETDRS 58 serum potassium 58 achieved statistical significance 58 serum HCV RNA 58 COPD exacerbation 58 % CI #.#-#.# [008] 58 periprocedural 58 mg tid 58 amoxicillin clavulanate 58 virologic response 58 anagrelide 58 FluCAM 58 paraprotein 58 experienced virologic failure 58 mg/m2 dose 58 A1c levels 57 febrile neutropenia 57 3mg/kg 57 infliximab monotherapy 57 nitroprusside 57 Likert scale 57 Ejection Fraction 57 timepoints 57 BMI z 57 oral prednisolone 57 mL sec 57 doxazosin 57 #mg doses [002] 57 rectal bleeding subscore 57 peginterferon alfa 2a 57 receiving INTRON 57 HAM D 57 International Prostate Symptom 57 statin monotherapy 57 Severity MSCS score 57 NYHA functional class 57 femoral neck BMD 57 Rate ORR 57 â ‰ ¥ 57 Peg IFN 57 atheroma volume 57 bronchial hyperresponsiveness 57 ug dose 57 CGIC 57 ziprasidone 57 incontinence episodes 57 #mg QD [002] 57 clodronate 57 Timed Walk 57 FACIT Fatigue 57 BPRS PSS 57 ULORIC 57 budesonide pMDI 57 diameter stenosis 57 LPV r 57 SUVmax 57 CI #.#-#.# [001] 57 #mg/day [001] 57 PASI 57 venlafaxine XR 57 RECIST Response Evaluation Criteria 57 tapentadol IR 57 XIENCE V PROMUS Stent 57 mcg Albuferon 57 SGOT 57 #μg [001] 57 AUA Symptom Score 57 ADHD Rating Scale 57 bezafibrate 57 leukocyte count 57 IIIa inhibitors 57 sustained virologic response 57 HbA 1C 57 partial remissions 57 depressive symptom 57 interrater reliability 57 irbesartan 57 glomerular filtration 57 rimonabant #mg 57 mg RDEA# 57 serum creatinine levels 57 serum HBV DNA 57 q#h 57 lamivudine monotherapy 57 mcg kg REBETOL 57 FOLFIRI alone 57 log# IU mL 57 flutamide 57 aripiprazole 57 achieved CCyR 57 biphasic insulin aspart 57 Febrile neutropenia 57 conjunctival hyperemia 57 NovoLog ® Mix 57 placebo PBO 57 GERD symptom 57 Fasting plasma glucose 57 TPV r 57 EDSS 57 Pharmacokinetic parameters 57 micrograms mL 57 posttreatment 57 p = ns 57 imipenem 57 lowest tertile 57 Hamilton Anxiety Scale 57 MIC# [001] 57 Secondary endpoints included 57 octreotide LAR 57 WOMAC scores 57 TMP SMX 57 nonsignificant 57 Primary endpoints 57 LVEF 57 clinically meaningful reductions 57 BARACLUDE ® 57 NPH insulin 57 placebo p = 57 p ≤ 57 aged ≥ 57 weekly CSBMs 57 postop 57 aspartate aminotransferase AST 57 preoperatively 57 HbA1C 57 Doxil ® 57 neurodevelopmental impairment 56 SELENA SLEDAI 56 sUA levels 56 dapagliflozin plus 56 PegIFN RBV 56 FOLFIRI 56 refractory ischemia 56 revascularizations 56 intracranial hemorrhage ICH 56 nmol L. 56 undetectable HCV RNA 56 scores TNSS 56 lamivudine refractory patients 56 rFSH 56 baseline FEV 56 mL/min/#.# m2 56 Zometa hazard 56 ECOG PS 56 Symptom Score 56 nocturnal awakenings 56 Pain Intensity 56 glycated hemoglobin 56 ‰ ¥ 56 achieved sustained virological 56 symptomatic intracranial hemorrhage 56 serum magnesium 56 IV bolus 56 non menstrual pelvic 56 KRAS mutations occur 56 mm Hg diastolic 56 urine albumin 56 AUC0 56 MACCE 56 PANSS scores 56 salmeterol fluticasone propionate 56 Solid Tumors criteria 56 μg d 56 Secondary endpoints include 56 maximal doses 56 fluoxetine paroxetine 56 CrCl 56 mCi kg 56 complete cytogenetic 56 serum clusterin levels 56 5-FU/LV 56 INVEGA ® 56 leucopenia 56 g trans fats 56 PSA nadir 56 ALT flares 56 HRQL 56 placebo fluoxetine 56 Hb A1c 56 dexmedetomidine 56 Impressions Improvement 56 pooled comparator 56 ribavirin therapy 56 DAS# scores 56 Clinician Administered PTSD 56 Key secondary endpoints 56 IFN alfa 56 atazanavir ritonavir 56 postoperative mortality 56 HBeAg + 56 fatigue asthenia 56 plus aztreonam 56 XIENCE V demonstrated 56 affective psychosis 56 seroprotection 56 postprocedure 56 OADs 56 glycosylated hemoglobin 56 ACTEMRA TM 56 DLTs 56 RECIST criteria 56 tirofiban 56 biochemical recurrence 56 Response Evaluation Criteria 56 Functioning GAF 56 placebo p 56 #mg dose [003] 56 daunorubicin 56 achieved sustained virologic 56 treatment emergent AEs 56 #mg q8h 56 cells uL 56 Lantus ® 56 APTIVUS r 56 Visual Analog Scale 56 serum cortisol 56 deep venous thromboses 56 uncorrected visual acuity 56 events SAEs 56 confidence intervals CIs 56 x ULN 56 Lucentis monotherapy 56 SGPT 56 Preoperatively 56 BENICAR HCT 56 TNF antagonist 56 discontinuations due 56 prespecified secondary 56 interferon ribavirin 56 nadroparin 56 dopamine partial agonist 56 μg kg 56 diuretic chlorthalidone 56 RNA copies mL 56 Visual acuity 56 mL kg 56 quetiapine risperidone 56 ONGLYZA saxagliptin 56 recurrent VTE 56 Stroke Scale NIHSS 56 Target Lesion Revascularization TLR 56 mg m² 56 T2 lesions 56 efavirenz EFV 56 IU mL 56 peripheral sensory neuropathy 56 baseline Hb 56 mg/m2/day 56 serum testosterone 56 virologic breakthrough 56 DOXIL 56 Ocular Surface Disease 56 SVR# 56 mmHg systolic 55 Neuropsychiatric Inventory 55 NATRECOR R 55 enalapril 55 CIMZIA TM certolizumab pegol 55 tacrolimus ointment 55 lispro alone 55 CFQ R 55 GLIADEL R Wafer 55 recurrent venous thromboembolism 55 atherogenic dyslipidemia 55 antimuscarinic 55 oral antidiabetes 55 serum urate levels 55 balsalazide 55 dosed intravenously 55 oral olanzapine 55 fluvastatin 55 salmeterol HFA MDI 55 serum phosphate levels 55 serum phosphorus 55 elevated creatinine 55 T2DM 55 Hamilton Rating Scale 55 oral corticosteroids 55 peak plasma concentrations 55 COMBIVIR 55 #mg BID [001] 55 q8h 55 Free Survival PFS 55 alanine aminotransferase ALT 55 Baseline characteristics 55 unfractionated heparin 55 Score IPSS 55 hepatorenal syndrome 55 serum phosphorous 55 angiographic outcomes 55 HBV DNA 55 estimated glomerular filtration 55 acute gout flares 55 steroid dexamethasone 55 #mg/day [002] 55 mCi m 2 55 COZAAR 55 1mg dose 55 coronary stenosis 55 CORE OM 55 TTM gross 55 severe NCI CTC 55 HBeAg 55 serum aminotransferase levels 55 receiving highly emetogenic 55 NIS LL 55 ug mL 55 gout flare 55 nmol l 55 detemir 55 intraobserver 55 nonvertebral fractures 55 femoral shaft fracture 55 ABC/3TC 55 methotrexate monotherapy 55 PCWP 55 Partial Response 55 RLAI 55 transaminase levels 55 posaconazole 55 response CCyR 55 ARCALYST ® 55 Secondary endpoints 55 paronychial inflammation 55 mucosal inflammation 55 tertile 55 interquartile range 55 hemoglobin A1C 55 iPTH 55 -5 -6 55 ng dl 55 poor metabolizers 55 endometrial thickness 55 -#.# mg dL [001] 55 linaclotide treated 55 fructosamine 55 lymphocyte count 55 docetaxel prednisone 55 transaminase elevations 55 MBq 55 Glasgow Coma Scale 55 subscale scores 55 bortezomib refractory 55 baseline serum creatinine 55 CHADS2 55 systolic dysfunction 55 leukopenia 55 rosuvastatin #mg 55 estimated GFR 55 relapsed MM 55 aPTT 55 % CI #.#-#.# [004] 55 perioperative mortality 55 #mg/dl 55 budesonide formoterol 55 abdominal pain flatulence 55 macroalbuminuria 55 aldosterone antagonist 55 progression TTP 55 HUMIRA achieved PASI 55 nadolol 55 Aptivus ® 55 IFN α 55 calculated creatinine clearance 55 sham injections 55 μg L 55 g dl 55 foveal thickness 55 FFNS 55 Hazard Ratio 55 symptomatic VTE 55 Brief Pain 55 diastolic hypertension 55 #mg BID [003] 55 saline placebo 55 AZT zidovudine Retrovir 55 mitoxantrone 55 creatinine clearance 55 serum IGF 55 acneform rash 55 antibody titer 55 zolmitriptan 55 advanced adenoma 55 PEG IFN 55 P = .# 55 antiretroviral naive 55 Fasting blood glucose 55 #.#ng/ml 55 plus ribavirin 55 intima media thickness 55 MULTAQ 55 virologic failure 55 sputum eosinophils 55 azacytidine 55 mean serum phosphorus 55 ZOMIG Nasal Spray 55 iodixanol 55 diastolic BP 55 #OHD 55 R# #mg BID 55 severe renal impairment 55 TAXUS p value 55 events MACE 55 ritonavir boosted 55 Sustained virologic response 55 #mg dose [001] 55 RSV hospitalizations 55 attain statistical significance 55 serum bilirubin 55 postoperative infections 55 acarbose 54 pmol L 54 Virologic 54 MS DRGs 54 Serious adverse reactions 54 mcg kg 54 dalteparin 54 PEPI 54 Postoperative complications 54 Copayments 54 prednisone prednisolone 54 peginterferon 54 Severe acneform rash 54 concomitant medications 54 Intro APR 54 PREZISTA r 54 OGTT 54 active comparator 54 cisplatin vinorelbine 54 mg simvastatin 54 preoperative chemotherapy 54 ANCOVA 54 systemic corticosteroids 54 undetectable viral loads 54 systemic embolism 54 blood Phe levels 54 dyslipidaemia 54 STN stimulation 54 dose cohort 54 thyrotropin levels 54 alicaforsen enema 54 #.#/#.# mm Hg [003] 54 logMAR 54 Fludara 54 receiving prophylactic anticoagulation 54 alfuzosin 54 PRADAXA #mg 54 splenectomized 54 mU liter 54 cells μL 54 interobserver reliability 54 pretreatment baseline 54 adalimumab 54 diastolic pressures 54 microalbumin test 54 proteinuria 54 neutropenia dehydration dyspnea 54 desvenlafaxine succinate 54 erythrocyte sedimentation rate 54 extrapyramidal symptoms 54 Ramipril 54 fosamprenavir 54 dyspnea 54 invasive aspergillosis 54 rotigotine 54 ropivacaine 54 ng dL 54 virological response 54 alteplase 54 intravitreal injections 54 Taxus Stent 54 FOLPI 54 mesalamine granules 54 Status Scale EDSS 54 ug ml 54 baseline LDH 54 umol L 54 VELCADE melphalan 54 Pegasys ® 54 intact parathyroid hormone 54 serum prostate 54 achieved mucosal healing 54 pegylated interferon alfa 2b 54 WOMAC TM 54 oral prednisone 54 adalimumab Humira 54 naïve HCV 54 PSADT 54 anastomotic leak 54 neutrophil count 54 symptomatic GERD 54 hypomagnesemia 54 log# 54 serum calcium levels 54 uM 54 AST ALT 54 prednisone prednisolone plus 54 microgram kg 54 QD dosing 54 Copegus ribavirin 54 azathioprine 54 lipid lowering agents 54 nonobese 54 Duration Gap 54 maximal dose 54 Raptiva r 54 intravenous bolus 54 discontinuations 54 fasting triglyceride levels 54 fasting plasma glucose 54 #mg/m# [001] 54 LANTUS R 54 ATACAND 54 ml kg 54 systemic corticosteroid 54 elevated transaminases 54 median PFS 54 #.#mmHg 54 inflammatory lesions 54 MMSE 54 H2RAs 54 hyperactivity impulsivity 54 isoprostane 54 INEGY 54 beclomethasone dipropionate 54 zidovudine lamivudine 54 timepoint 54 QoL 54 perioperative complications 54 composite endpoint 54 PRADAXA 54 Non Responders 54 mg eq 54 CIBIC plus 54 dose GATTEX 54 HBeAg positive 54 vitreous haze 54 genotypic resistance 54 patients evaluable 54 hypoglycemic episodes 54 highest tertile 54 benazepril 54 Kaplan Meier estimates 54 hepatitis C genotype 54 dyspareunia 54 median CD4 54 unfractionated heparin UFH 54 simvastatin #mg 54 NNRTI resistance 54 NMIBC 54 UACR 54 #.#/#.# mm Hg [001] 54 symptom exacerbation 54 Partial Responses 54 dose colchicine 54 #ng/ml 54 bosentan 54 fraction LVEF 54 plasma leptin 54 erection hardness 54 serum CRP 54 neuropathy sensory 54 plasma cortisol 54 NATRECOR ® 54 dyspnoea 54 HBeAg positive patients 54 mcg kg min 54 Mania Rating Scale 54 paresthesias 54 postoperative morbidity 54 ischemia driven 54 Depression Rating Scale 54 ≥ 54 Peginterferon Alfa 2a 54 mmol liter 54 nmol 54 μg dL 54 mcg linaclotide 54 laboratory abnormalities 54 RAPTIVA 54 hyperemia 54 nondepressed 54 racemic albuterol 54 advanced adenomas 54 mcg doses 54 BENICAR 54 Adverse events 54 glargine 54 HRQOL 54 gastric pH 54 Solid Tumors 54 EBMT criteria 54 apnea hypopnea 54 ejaculatory function 54 doripenem 54 CK # plasma concentrations 54 micromolar 54 subscales 54 euthyroid 54 #mmHg [002] 54 mg/# hours 54 HMG CoA reductase inhibitor 54 undetectable viral load 54 mmHg p = 54 oxygen desaturation 54 concomitant AEDs 54 mIU ml 54 Apgar scores 54 plus OBT 54 Cronbach alpha 54 nighttime awakenings 54 peginterferon alfa 2b 54 dacarbazine 54 Visual Analog 54 virological failure 54 hemoglobin concentrations 54 CSBMs 54 adenoma recurrence 54 prospectively stratified 54 intraclass correlation coefficient 54 mmol kg 54 myalgia arthralgia 54 oxycodone IR 54 CsA 54 BENCHMRK 54 rapid virologic response 54 Charlson comorbidity index 54 enzyme elevations 54 doxorubicin cyclophosphamide 54 PEGINTRON TM 54 neutropenic fever 54 nonfatal myocardial infarction MI 54 mEq 53 target lesion revascularizations 53 blood Phe 53 Non inferiority 53 asymptomatic carotid stenosis 53 serum LDL cholesterol 53 metformin sulfonylurea 53 Durezol 53 median survivals 53 postoperative complication 53 Inventory BPI 53 LEXIVA 53 milliliters mL 53 oxcarbazepine 53 dose Iluvien 53 pulmonary exacerbations 53 subthreshold depression 53 Loss severities 53 pain subscale 53 LOVENOX 53 aminotransferase levels 53 serum sodium levels 53 unresectable HCC 53 nonresponders 53 rFVIIa 53 IFL chemotherapy regimen 53 Mg Uk 53 dacarbazine chemotherapy 53 FTE staffing 53 Cholinesterase Inhibitors 53 jana.mlcochova @ thomson.com 53 KOOS 53 nephrotoxicity 53 Likert pain 53 antiretroviral naïve 53 transaminases 53 CPAP adherence 53 platelet reactivity 53 #ug [001] 53 Hematologic toxicity 53 pegylated alpha interferon 53 STELARA ® 53 urinary albumin 53 follicular lymphomas 53 Pegylated Liposomal Doxorubicin 53 Rating Scale IRLS 53 IQR 53 mg q#h 53 aminotransferases 53 mRCC